(Q39525572)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21668581%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

title

Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21668581%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21668581%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

author name string

Shiro Suzuki

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21668581%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Toshiaki Yoshikawa

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21668581%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Tomoya Hirosawa

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21668581%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Kiyosumi Shibata

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21668581%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Fumitaka Kikkawa

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21668581%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Tetsuya Nakatsura

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21668581%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

publication date

8 July 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21668581%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21668581%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

volume

102

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21668581%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21668581%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

page(s)

1622-1629

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21668581%20AND%20SRC:MED&resulttype=core&format=json

Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy

4 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02003.X

Ovarian clear cell adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02003.X

Glypicans: proteoglycans with a surprise

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02003.X

Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02003.X

Identification of glypican-3 as a novel tumor marker for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02003.X

Glypican-3 expression in Wilms tumor and hepatoblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02003.X

Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02003.X

Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02003.X

HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02003.X

Efficient cloning and expression of HLA class I cDNA in human B-lymphoblastoid cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02003.X

Growth-suppressing function of glypican-3 (GPC3) via insulin like growth factor II (IGF-II) signaling pathway in ovarian clear cell carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02003.X

Highly sensitive detection of melanoma at an early stage based on the increased serum secreted protein acidic and rich in cysteine and glypican-3 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02003.X

Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02003.X

Detection of glypican-3-specific CTLs in chronic hepatitis and liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02003.X

Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02003.X

Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02003.X

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02003.X

Cancer vaccines: moving beyond current paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02003.X

Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02003.X

Myeloid-derived suppressor cells as regulators of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02003.X

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02003.X

Differential role of Fas/Fas ligand interactions in cytolysis of primary and metastatic colon carcinoma cell lines by human antigen-specific CD8+ CTL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02003.X

Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02003.X

Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02003.X